Amgen Inc.
Pegylated carfilzomib compounds
Last updated:
Abstract:
The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I ##STR00001## wherein R.sup.1, R.sup.2, linker, PEG, n and o are as defined herein.
Status:
Grant
Type:
Utility
Filling date:
23 Apr 2020
Issue date:
3 Aug 2021